Clinical Trials
62 trialsN2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
STIR
Medical College of Wisconsin
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
Milton S. Hershey Medical Center
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Milton S. Hershey Medical Center
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
Milton S. Hershey Medical Center
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
UVA-Gen001
University of Virginia
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
Memorial Sloan Kettering Cancer Center
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
GA-68
University of Iowa
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
Cancer Research UK
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
University of Pittsburgh
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Barbara Ann Karmanos Cancer Institute
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
PEPI
Baylor College of Medicine
SPRING
Baylor College of Medicine
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
DOTA-TOC
University of California, San Francisco
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Memorial Sloan Kettering Cancer Center
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
M.D. Anderson Cancer Center
STALLONe
Children's Mercy Hospital Kansas City
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
University of California, San Francisco
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota